Cargando…

The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients

INTRODUCTION: Imatinib mesylate is the drug of choice for patients with chronic myeloid leukemia (CML). Imatinib pharmacokinetics is affected by a number of transport proteins and enzymes. MATERIAL AND METHODS: In the present study we evaluated the association of eight polymorphisms in the seven gen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Belohlavkova, Petra, Vrbacky, Filip, Voglova, Jaroslava, Racil, Zdenek, Zackova, Daniela, Hrochova, Katerina, Malakova, Jana, Mayer, Jiri, Zak, Pavel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2018
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209720/ https://www.ncbi.nlm.nih.gov/pubmed/30393497 http://dx.doi.org/10.5114/aoms.2018.73538

Ejemplares similares

MonoMAC syndrome with GATA2 novel mutation: A case report
por: Belohlavkova, Petra, et al.
Publicado: (2022)

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment
por: Jaruskova, Monika, et al.
Publicado: (2017)

Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia
por: Knight, Andrea, et al.
Publicado: (2022)

Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels
por: Klamová, Hana, et al.
Publicado: (2013)

Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy
por: Pavlík, Tomáš, et al.
Publicado: (2011)

P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE
por: Semerad, Lukas, et al.
Publicado: (2023)

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects
por: Culen, Martin, et al.
Publicado: (2016)

Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome
por: Belohlavkova, P, et al.
Publicado: (2021)

Intensive Care Infection Score (ICIS) is elevated in patients with moderate and severe COVID-19 in the early stages of disease
por: Vrbacky, Filip, et al.
Publicado: (2022)

Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin
por: Kuželová, Kateřina, et al.
Publicado: (2018)

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
por: Estrada, Natalia, et al.
Publicado: (2021)

The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
por: Zhu, Yu, et al.
Publicado: (2016)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014)

A Geodemographic View of the Accessibility of Selected Outpatient Services in Czechia
por: Maláková, Kateřina
Publicado: (2022)

Imatinib plus Granulocyte Colony-Stimulating Factor in Chronic Myeloid Leukemia Patients Who Have Achieved Partial or Complete Cytogenetic Response while on Imatinib
por: Fang, Baijun, et al.
Publicado: (2011)

A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel
por: Šestáková, Šárka, et al.
Publicado: (2022)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia
por: Šimkovič, Martin, et al.
Publicado: (2015)

Spatial Healthcare Accessibility: A District-Level Analysis of Travel for Outpatient Diabetology in Czechia
por: Šídlo, Luděk, et al.
Publicado: (2022)

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib
por: Breccia, Massimo, et al.
Publicado: (2017)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
por: Cortes, Jorge E., et al.
Publicado: (2020)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil
por: Rego, Monica Napoleão Fortes, et al.
Publicado: (2015)

Digital PCR can provide improved BCR-ABL1 detection in chronic myeloid leukemia patients in deep molecular response and sensitivity of standard quantitative methods using EAC assays
por: Smitalova, Dagmar, et al.
Publicado: (2021)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model
por: Lindström, H. Jonathan G., et al.
Publicado: (2022)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
por: Bilajac, Esma, et al.
Publicado: (2022)

Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment
por: Russo, D, et al.
Publicado: (2015)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

A Single Nucleotide Polymorphism in cBIM Is Associated with a Slower Achievement of Major Molecular Response in Chronic Myeloid Leukaemia Treated with Imatinib
por: Augis, Vanessa, et al.
Publicado: (2013)

Successful Peripheral Blood Stem Cells Collection in Imatinib Pretreated and Nilotinib-Treated Chronic Myeloid Leukemia Patient
por: Vokurka, Samuel, et al.
Publicado: (2010)

Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
por: Go, Seong Woo, et al.
Publicado: (2013)

Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile
por: Kreutzman, Anna, et al.
Publicado: (2011)

Synthesis and Characterization of Telmisartan‐Derived Cell Death Modulators to Circumvent Imatinib Resistance in Chronic Myeloid Leukemia
por: Schoepf, Anna M., et al.
Publicado: (2020)

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
por: Gemelli, Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ltaei1pogll1cras6ples0ee7k